Efficient transduction of vascular smooth muscle cells with a translational AAV2.5 vector: A new perspective for in-stent restenosis gene therapy

Gene Therapy

Volumn 20, Issue 9, 2013, Pages 901-912

  Lompre A M ^a,b,f   Hadri, L ^c,f   Merlet, E ^a,b,f   Keuylian, Z ^b,f   Mougenot, N ^b   Karakikes, I ^c,f   Chen, J ^c,f   Atassi, F ^a,b,f   Marchand, A ^a,b,f   Blaise, R ^b   Limon, I ^b,f   Mcphee, S W J ^d   Samulski, R J ^e   Hajjar, R J ^c,f   Lipskaia, L ^a,b,c,f  

^a Sorbonne Universités   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d ASKLEPIOS BIOPHARMACEUTICAL INC   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f INSERM   (France)

Author keywords

restenosis; vascular smooth muscle cells; virus vector

Indexed keywords

CARDIOVASCULAR AGENT; GREEN FLUORESCENT PROTEIN; MESSENGER RNA; PARVOVIRUS VECTOR; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 2A; UNCLASSIFIED DRUG;

ADENO ASSOCIATED VIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL WALL THICKENING; ARTERY INTIMA PROLIFERATION; CAROTID ARTERY; CAROTID ARTERY INJURY; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; HUMAN; HUMAN CELL; IN VITRO GENE TRANSFER; IN VITRO STUDY; IN-STENT RESTENOSIS; MALE; MORPHOMETRICS; NEOINTIMA; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; SEROTYPE; SMOOTH MUSCLE FIBER; STRAIN DIFFERENCE; TRANSGENE; VASCULAR SMOOTH MUSCLE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS STRAIN;

ADENO-ASSOCIATED VIRUS; HUMAN ADENOVIRUS TYPE 5; RATTUS;

ACTINS; ANIMALS; CAROTID ARTERIES; CELLS, CULTURED; CORONARY RESTENOSIS; CORONARY VESSELS; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; GENETIC THERAPY; GENETIC VECTORS; HUMANS; MALE; MUSCLE, SMOOTH, VASCULAR; NEOINTIMA; RATS; RATS, SPRAGUE-DAWLEY; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; TRANSDUCTION, GENETIC;

EID: 84883856521     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2013.13     Document Type: Review

References (61)

1. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G et al. Executive summary: heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010; 121: 948-954.
2. Robertson KE, McDonald RA, Oldroyd KG, Nicklin SA, Baker AH. Prevention of coronary in-stent restenosis and vein graft failure: does vascular gene therapy have a role? Pharmacol Ther 2012; 136: 23-34.
3. Rutanen J, Puhakka H, Yla-Herttuala S. Post-intervention vessel remodeling. Gene Therapy 2002; 9: 1487-1491. (Pubitemid 35414783)
4. Curcio A, Torella D, Indolfi C. Mechanisms of smooth muscle cell proliferation and endothelial regeneration after vascular injury and stenting: approach to therapy. Circ J 2011; 75: 1287-1296.
5. Gaffney MM, Hynes SO, Barry F, O'Brien T. Cardiovascular gene therapy: current status and therapeutic potential. Br J Pharmacol 2007; 152: 175-188. (Pubitemid 47517600)
6. Jaski BE, Jessup ML, Mancini DM, Cappola TP, Pauly DF, Greenberg B et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. J Card Fail 2009; 15: 171-181.
7. Jessup M, Greenberg B, Mancini D, Cappola T, Pauly DF, Jaski B et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2\+-ATPase in patients with advanced heart failure. Circulation 2012; 124: 304-313.
8. Lipskaia L, del Monte F, Capiod T, Yacoubi S, Hadri L, Hours M et al. Sarco/endoplasmic reticulum Ca2\+-ATPase gene transfer reduces vascular smooth muscle cell proliferation and neointima formation in the rat. Circ Res 2005; 97: 488-495. (Pubitemid 41298180)
9. Lipskaia L, Hadri L, Le Prince P, Esposito B, Atassi F, Liang L et al. SERCA2a gene transfer prevents intimal proliferation in an organ culture of human internal mammary artery. Gene Therapy 2012; e-pub ahead of print 5 July 2012; doi:10.1038/gt.2012.50.
10. Merlet E, Lipskaia L, Marchand A, Hadri L, Mougenot N, Atassi F et al. A calcium-sensitive promoter construct for gene therapy. Gene Therapy 2013; 20: 248-254.
11. Bobe R, Hadri L, Lopez JJ, Sassi Y, Atassi F, Karakikes I et al. SERCA2a controls the mode of agonist-induced intracellular Ca2\+ signal, transcription factor NFAT and proliferation in human vascular smooth muscle cells. J Mol Cell Cardiol 2011; 50: 621-633.
12. White K, Nicklin SA, Baker AH. Novel vectors for in vivo gene delivery to vascular tissue. Expert Opin Biol Ther 2007; 7: 809-821. (Pubitemid 46954428)
13. Gruchala M, Bhardwaj S, Pajusola K, Roy H, Rissanen TT, Kokina I et al. Gene transfer into rabbit arteries with adeno-associated virus and adenovirus vectors. J Gene Med 2004; 6: 545-554. (Pubitemid 40228070)
14. Schulick AH, Dong G, Newman KD, Virmani R, Dichek DA. Endothelium-specific in vivo gene transfer. Circ Res 1995; 77: 475-485.
15. Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994; 91: 4407-4411. (Pubitemid 24143442)
16. Guzman RJ, Lemarchand P, Crystal RG, Epstein SE, Finkel T. Efficient and selective adenovirus-mediated gene transfer into vascular neointima. Circulation 1993; 88: 2838-2848. (Pubitemid 23360211)
17. Guzman RJ, Lemarchand P, Crystal RG, Epstein SE, Finkel T. Efficient gene transfer into myocardium by direct injection of adenovirus vectors. Circ Res 1993; 73: 1202-1207. (Pubitemid 23340215)
18. Hartman ZC, Appledorn DM, Amalfitano A. Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Res 2008; 132: 1-14. (Pubitemid 351232078)
19. Di Paolo NC, Miao EA, Iwakura Y, Murali-Krishna K, Aderem A, Flavell RA et al. Virus binding to a plasma membrane receptor triggers interleukin-1 alpha-mediated proinflammatory macrophage response in vivo. Immunity 2009; 31: 110-121.
20. Alba R, Bradshaw AC, Coughlan L, Denby L, McDonald RA, Waddington SN et al. Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors. Blood 2010; 116: 2656-2664.
21. Wu Z, Asokan A, Samulski RJ. Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther 2006; 14: 316-327. (Pubitemid 44184972)
22. Bowles DE, McPhee SW, Li C, Gray SJ, Samulski JJ, Camp AS et al. Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol Ther 2012; 20: 443-455.
23. Summerford C, Samulski RJ. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 1998; 72: 1438-1445. (Pubitemid 28116931)
24. Gnatenko D, Arnold TE, Zolotukhin S, Nuovo GJ, Muzyczka N, Bahou WF. Characterization of recombinant adeno-associated virus-2 as a vehicle for gene delivery and expression into vascular cells. J Investig Med 1997; 45: 87-98. (Pubitemid 127453341)
25. Maeda Y, Ikeda U, Ogasawara Y, Urabe M, Takizawa T, Saito T et al. Gene transfer into vascular cells using adeno-associated virus (AAV) vectors. Cardiovasc Res 1997; 35: 514-521. (Pubitemid 27469413)
26. Richter M, Iwata A, Nyhuis J, Nitta Y, Miller AD, Halbert CL et al. Adeno-associated virus vector transduction of vascular smooth muscle cells in vivo. Physiol Genomics 2000; 2: 117-127.
27. Vassalli G, Bueler H, Dudler J, von Segesser LK, Kappenberger L. Adeno-associated virus (AAV) vectors achieve prolonged transgene expression in mouse myocardium and arteries in vivo: a comparative study with adenovirus vectors. Int J Cardiol 2003; 90: 229-238. (Pubitemid 37087882)
28. Chen S, Kapturczak M, Loiler SA, Zolotukhin S, Glushakova OY, Madsen KM et al. Efficient transduction of vascular endothelial cells with recombinant adenoassociated virus serotype 1 and 5 vectors. Hum Gene Ther 2005; 16: 235-247. (Pubitemid 40344215)
29. Zabner J, Seiler M, Walters R, Kotin RM, Fulgeras W, Davidson BL et al. Adenoassociated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer. J Virol 2000; 74: 3852-3858. (Pubitemid 30180327)
30. Sen S, Conroy S, Hynes SO, McMahon J, O'Doherty A, Bartlett JS et al. Gene delivery to the vasculature mediated by low-titre adeno-associated virus serotypes 1 and 5. J Gene Med 2008; 10: 143-151. (Pubitemid 351267156)
31. Mendell JR, Campbell K, Rodino-Klapac L, Sahenk Z, Shilling C, Lewis S et al. Dystrophin immunity in Duchenne's muscular dystrophy. N Engl J Med 2010; 363: 1429-1437.
32. Indolfi C, Torella D, Coppola C, Stabile E, Esposito G, Curcio A et al. Rat carotid artery dilation by PTCA balloon catheter induces neointima formation in presence of IEL rupture. Am J Physiol Heart Circ Physiol 2002; 283: H760-H767. (Pubitemid 34790872)
33. Lipskaia L, Pourci ML, Delomenie C, Combettes L, Goudouneche D, Paul JL et al. Phosphatidylinositol 3-kinase and calcium-activated transcription pathways are required for VLDL-induced smooth muscle cell proliferation. Circ Res 2003; 92: 1115-1122. (Pubitemid 36665857)
34. Karpurapu M, Wang D, Van Quyen D, Kim TK, Kundumani-Sridharan V, Pulusani S et al. Cyclin D1 is a bona fide target gene of NFATc1 and is sufficient in the mediation of injury-induced vascular wall remodeling. J Biol Chem 2010; 285: 3510-3523.
35. Rolling F, Nong Z, Pisvin S, Collen D. Adeno-associated virus-mediated gene transfer into rat carotid arteries. Gene Therapy 1997; 4: 757-761. (Pubitemid 27380156)
36. Work LM, Nicklin SA, Brain NJ, Dishart KL, Von Seggern DJ, Hallek M et al. Development of efficient viral vectors selective for vascular smooth muscle cells. Mol Ther 2004; 9: 198-208. (Pubitemid 38256546)
37. Nicklin SA, Buening H, Dishart KL, de Alwis M, Girod A, Hacker U et al. Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol Ther 2001; 4: 174-181. (Pubitemid 32851280)
38. White SJ, Nicklin SA, Buning H, Brosnan MJ, Leike K, Papadakis ED et al. Targeted gene delivery to vascular tissue in vivo by tropism-modified adeno-associated virus vectors. Circulation 2004; 109: 513-519. (Pubitemid 38168515)
39. Johnson JS, Li C, DiPrimio N, Weinberg MS, McCown TJ, Samulski RJ. Mutagenesis of adeno-associated virus type 2 capsid protein VP1 uncovers new roles for basic amino acids in trafficking and cell-specific transduction. J Virol 2010; 84: 8888-8902.
40. Hadri L, Bobe R, Kawase Y, Ladage D, Ishikawa K, Atassi F et al. SERCA2a gene transfer enhances eNOS expression and activity in endothelial cells. Mol Ther 2010; 18: 1284-1292.
41. Jang JH, Schaffer DV, Shea LD. Engineering biomaterial systems to enhance viral vector gene delivery. Mol Ther 2011; 19: 1407-1415.
42. Wang K, Kessler PD, Zhou Z, Penn MS, Forudi F, Zhou X et al. Local adenoviralmediated inducible nitric oxide synthase gene transfer inhibits neointimal formation in the porcine coronary stented model. Mol Ther 2003; 7: 597-603. (Pubitemid 36626239)
43. Fishbein I, Alferiev I, Bakay M, Stachelek SJ, Sobolewski P, Lai M et al. Local delivery of gene vectors from bare-metal stents by use of a biodegradable synthetic complex inhibits in-stent restenosis in rat carotid arteries. Circulation 2008; 117: 2096-2103. (Pubitemid 351572181)
44. Uchida Y, Uchida Y, Matsuyama A, Koga A, Kanai M, Sakurai T. Formation of weband membrane-like structures on the edges of bare-metal coronary stents. Circ J 2010; 74: 1830-1836.
45. Ueda M, Becker AE, Naruko T, Kojima A. Smooth muscle cell de-differentiation is a fundamental change preceding wound healing after percutaneous transluminal coronary angioplasty in humans. Coron Artery Dis 1995; 6: 71-81.
46. Lipskaia L, Limon I, Bobe R, Hajjar RJ. Calcium cycling in synthetic and contractile phasic or tonic vascular smooth muscle cells. In: Sugi H (ed) Current Basic and Pathological Approaches to the Function of Muscle Cells and Tissues-From Molecules to Humans. InTech, 2012.
47. Tanner FC, Meier P, Greutert H, Champion C, Nabel EG, Luscher TF. Nitric oxide modulates expression of cell cycle regulatory proteins: a cytostatic strategy for inhibition of human vascular smooth muscle cell proliferation. Circulation 2000; 101: 1982-1989. (Pubitemid 30225281)
48. Byrne MJ, Power JM, Preovolos A, Mariani JA, Hajjar RJ, Kaye DM. Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals. Gene Therapy 2008; 15: 1550-1557.
49. Kawase Y, Ly HQ, Prunier F, Lebeche D, Shi Y, Jin H et al. Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J Am Coll Cardiol 2008; 51: 1112-1119. (Pubitemid 351374774)
50. Hajjar RJ, Zsebo K, Deckelbaum L, Thompson C, Rudy J, Yaroshinsky A et al. Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure. J Card Fail 2008; 14: 355-367. (Pubitemid 351756538)
51. Csiszar A, Ungvari Z, Koller A, Edwards JG, Kaley G. Aging-induced proinflammatory shift in cytokine expression profile in coronary arteries. Faseb J 2003; 17: 1183-1185.
52. Morishita R. Lessons from human arteries: how to design a gene therapy strategy for treatment of cardiovascular disease. Circ Res 1998; 82: 1349-1351. (Pubitemid 28294755)
53. Rekhter MD, Simari RD, Work CW, Nabel GJ, Nabel EG, Gordon D. Gene transfer into normal and atherosclerotic human blood vessels. Circ Res 1998; 82: 1243-1252. (Pubitemid 28294743)
54. Janssens SP. Applied gene therapy in preclinical models of vascular injury. Curr Atheroscler Rep 2003; 5: 186-190. (Pubitemid 38898872)
55. Laitinen M, Hartikainen J, Hiltunen MO, Eranen J, Kiviniemi M, Narvanen O et al. Catheter-mediated vascular endothelial growth factor gene transfer to human coronary arteries after angioplasty. Hum Gene Ther 2000; 11: 263-270. (Pubitemid 30080384)
56. Hedman M, Hartikainen J, Syvanne M, Stjernvall J, Hedman A, Kivela A et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 2003; 107: 2677-2683. (Pubitemid 36667240)
57. Kutryk MJ, Foley DP, van den Brand M, Hamburger JN, van der Giessen WJ, deFeyter PJ et al. Local intracoronary administration of antisense oligonucleotide against c-myc for the prevention of in-stent restenosis: results of the randomized investigation by the Thoraxcenter of antisense DNA using local delivery and IVUS after coronary stenting (ITALICS) trial. J Am Coll Cardiol 2002; 39: 281-287. (Pubitemid 34084634)
58. Kipshidze N, Iversen P, Overlie P, Dunlap T, Titus B, Lee D et al. First human experience with local delivery of novel antisense AVI-4126 with Infiltrator catheter in de novo native and restenotic coronary arteries: 6-month clinical and angiographic follow-up from AVAIL study. Cardiovasc Revasc Med 2007; 8: 230-235. (Pubitemid 350161452)
59. del Monte F, Harding SE, Schmidt U, Matsui T, Kang ZB, Dec GW et al. Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a. Circulation 1999; 100: 2308-2311.
60. Eggermont JA, Wuytack F, Verbist J, Casteels R. Expression of endoplasmic-reticulum Ca2(\+)-pump isoforms and of phospholamban in pig smooth-muscle tissues. Biochem J 1990; 271: 649-653. (Pubitemid 20384596)
61. Keuylian Z, de Baaij JH, Glorian M, Rouxel C, Merlet E, Lipskaia L et al. The Notch pathway attenuates interleukin 1beta (IL1beta)-mediated induction of adenylyl cyclase 8 (AC8) expression during vascular smooth muscle cell (VSMC) transdifferentiation. J Biol Chem 2012; 287: 24978-24989.